ESMO 2017 | The potential of biosimilars in cancer treatment

Richard Markus

Biosimilars are a promising new addition as a novel treatment option for patients of cancer. Richard Markus, MD, PhD, from Amgen, Los Angeles, CA shares with us his feelings on the attention that biosimilars are gaining from experts in the field, and explains their importance as a new class for cancer treatment. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

Share this video